Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
Targeting PI3K/Akt signal transduction for cancer therapy
Y He, MM Sun, GG Zhang, J Yang, KS Chen… - Signal transduction and …, 2021 - nature.com
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …
structures or functions that are difficult to interfere with using conventional drug design …
Targeting Akt in cancer for precision therapy
H Hua, H Zhang, J Chen, J Wang, J Liu… - Journal of Hematology & …, 2021 - Springer
Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
[PDF][PDF] Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors
The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
The biology and management of non-small cell lung cancer
RS Herbst, D Morgensztern, C Boshoff - Nature, 2018 - nature.com
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …
achieved over the past two decades, increasing our understanding of the disease biology …
Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi
Genetic and epigenetic changes in DNA are involved in cancer development and tumor
progression. Histone deacetylases (HDACs) are key regulators of gene expression that act …
progression. Histone deacetylases (HDACs) are key regulators of gene expression that act …
[HTML][HTML] A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
CY Huang, DT Ju, CF Chang, PM Reddy… - Biomedicine, 2017 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …